PhD Studentship – Bioprocess: Skeletal Editing of Therapeutic Nucleosides
The University of Manchester
Manchester, United Kingdom
General Description – include all relevant details from the source
The University of Manchester’s School of Chemistry invites applications for a fully funded PhD studentship in Bioprocess: Skeletal Editing of Therapeutic Nucleosides. This research opportunity offers a 3.5-year doctoral programme starting in 2026, situated within a vibrant and collaborative research environment. The project will explore innovative bioprocess strategies and skeletal editing methodologies to create and optimise novel therapeutic nucleoside structures, advancing the frontiers of synthetic and medicinal chemistry. Research will span the development and application of cutting-edge organic synthesis, analytical techniques, and biocatalytic processes. The successful candidate will work closely with leading faculty, contributing to impactful research with potential implications for drug discovery and bioprocess development.
Eligibility Criteria
Applicants should hold, or be on track to obtain, a first-class honours degree (or equivalent) in chemistry or a closely related discipline. Applicants must demonstrate a strong academic record and a keen interest in research. While the studentship is primarily available to home students, all eligible applicants should check individual funding criteria.
Required expertise/skills
Ideal candidates will have substantial laboratory experience in organic chemistry, including familiarity with chemical synthesis, reaction optimisation, and analytical characterisation techniques. Ability to think independently, work collaboratively in a research team, and engage with complex scientific problems is essential.
Salary details
The studentship includes a tax-free annual stipend set at the UKRI minimum rate (approximately £20,780 for 2025/26), with tuition fees fully covered at the home rate. Stipend increases are expected each year.
Application Deadline
The closing date for applications is 31 March 2026.